FDA Considers Easing Industry Burden In AF Ablation Catheter Trial Design

FDA may be willing to accept a reduction of symptoms as the primary endpoint for atrial fibrillation ablation catheter clinical trials, according to CDRH Cardiac Electrophysiology & Monitoring Devices Branch Medical Officer Randall Brockman, MD